Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Shanghai Pharmaceuticals Holding Co Ltd
Note Receivable
Shanghai Pharmaceuticals Holding Co Ltd
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Note Receivable
¥332m
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
1%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Note Receivable
¥109.8m
|
CAGR 3-Years
123%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shanghai Pharmaceuticals Holding Co Ltd
Glance View
Shanghai Pharmaceuticals Holding Co Ltd, a giant in China's pharmaceutical industry, operates with a dual-engine strategy that seamlessly combines manufacturing and distribution. Established in the bustling metropolis of Shanghai, the company has swiftly become a cornerstone of China's healthcare landscape. Its manufacturing arm is a powerhouse of innovation and production, turning out a vast array of pharmaceutical products that encompass both traditional Chinese medicine and modern pharmaceuticals. These products range from patented medicines to essential generics, entering hospitals, clinics, and retail pharmacies nationwide, all the while feeding a robust supply chain that caters to the country's vast and diverse market needs. On the flip side, Shanghai Pharmaceuticals' extensive distribution network is the lifeline that ensures these vital medicines reach their destinations safely and efficiently. In an era where logistics and supply chain management are pivotal, the company excels through an advanced distribution system that connects manufacturers with end-users across China. This network is bolstered by strategic partnerships and a commitment to technological advancement, allowing the company to maintain agility and reliability in an ever-evolving market. Revenue streams flow not just from product sales but are heavily supplemented through strategic partnerships and services that enhance accessibility and affordability for healthcare providers and patients alike. As one of the top pharmaceutical firms in China, Shanghai Pharmaceuticals is adept at maneuvering the intricacies of healthcare demands, regulatory landscapes, and competitive dynamics, carving its niche as a leader in both innovation and distribution efficiency.
See Also
What is Shanghai Pharmaceuticals Holding Co Ltd's Note Receivable?
Note Receivable
332m
CNY
Based on the financial report for Sep 30, 2025, Shanghai Pharmaceuticals Holding Co Ltd's Note Receivable amounts to 332m CNY.
What is Shanghai Pharmaceuticals Holding Co Ltd's Note Receivable growth rate?
Note Receivable CAGR 10Y
1%
Over the last year, the Note Receivable growth was -42%. The average annual Note Receivable growth rates for Shanghai Pharmaceuticals Holding Co Ltd have been 13% over the past three years , 9% over the past five years , and 1% over the past ten years .